Transcriptional co-activator with PDZ-binding motif (TAZ) is a downstream effector of the Hippo signaling pathway that participates in tumorigenesis. The aim of this study was to identify the miRNA counterpart for TAZ and elucidate the mechanism underlying the tumorigenic effect of TAZ. We demonstrated that TAZ is upregulated in osteosarcoma (OS) tissues and cell lines, and that TAZ overexpression can induce cell migration, invasion and proliferation. Moreover, miRNA-224 (miR-224), a TAZ phenocopy that functions downstream of TAZ, was found to be upregulated with TAZ overexpression. Further, a mechanistic study revealed that miR-224 functions by inhibiting the tumor suppressor, SMAD4, to support the proliferation and migration of OS cells. Our findings indicate that targeting TAZ and miR-224 could be a promising approach for the treatment of OS.
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Osteosarcoma (OS) is the most common primary malignant bone tumor diagnosed in young people below the age of 20. Formerly, patients with only localized disease were treated with surgery alone, leading to a low survival rate of 20%. This may be attributed to overlooking the micrometastasis likely present at diagnosis. 1 Nowadays, the 5-year survival rate has risen to approximately 60-70%, owing to cooperative treatment of localized tumor with neoadjuvants. 2 However, the 5-year survival rate of patients with metastatic tumor remains low at only 30%. 3 In addition, valid chemotherapy has been constrained by the development of chemoresistance, especially multi-drug resistance, after continuous treatment. Under these circumstances, further refinement with cytotoxic chemotherapy regimens is unlikely. 4 Hence, novel therapeutic approaches based on targeting oncogenic driver pathways in OS are needed urgently.
The Hippo signaling pathway has a critical role in organ size control, tissue homeostasis and tumorigenesis, 5, 6 and dysregulation of the Hippo pathway exerts significant impact on malignant transformation. 7 Mst1/2 are pro-apoptotic kinases and core components of the Hippo pathway; Mst1/2 are activated by caspase-mediated cleavage upon apoptotic stress. Subsequently, Lats1/2 are activated and phosphorylated. 8 The major downstream effectors of the Hippo pathway are Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ), 8 which can be phosphorylated and inactivated by Lats1/2 in complex with the scaffold protein Mob1. [8] [9] [10] [11] As transcription coactivators, YAP/TAZ activate gene expression by interacting with the TEAD family of transcription factors. [12] [13] [14] Increasing evidence has confirmed the aberrant expression of TAZ in multiple human tumors, including breast cancer, lung cancer and hepatocellular carcinoma. [15] [16] [17] Moreover, it has been demonstrated that TAZ can function as an oncogene, activating TEAD-mediated gene transcription to promote tissue growth and inhibit apoptosis. 15, 16 However, the downstream function of YAP/TAZ in the Hippo signaling pathway remains unclear.
MicroRNAs (miRNAs) are a class of 22-nucleotide noncoding RNAs that have emerged as critical components of the gene regulatory networks controlling numerous important pathophysiological processes, including the initiation and progression of cancers. Dysregulated miRNA has been demonstrated to have critical roles in OS. 18, 19 Shen et al.
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reported that miR-130a is directly induced by YAP, leading to the amplification of YAP activity. A similar mechanism has been reported in the case of Bantam -a well-known Ykiinduced miRNA in Drosophila. 20, 21 Moreover, YAP has been identified as a regulator of global miRNA biogenesis via modulation of the miRNA-processing enzymes, microprocessor or Dicer complex, suggesting a transcription-independent role for YAP. 22, 23 Tumor growth factor (TGF)-β has a confirmed yet complicated role in directing the autonomous, local and systemic cellular responses that together regulate the initiation, progression and prognostic outcome of human cancers. [24] [25] [26] Other pathways altered in human cancer may also contribute to the TGF-β-mediated regulation of tumorigenesis to some extent. 27, 28 During initiation and early progression of the tumor, TGF-β serves as a tumor suppressor by inhibiting proliferation and accelerating apoptosis, as evidenced by the fact that loss or mutation of the members of the TGF-β signaling pathway in humans causes unregulated cell growth and eventually, cancer. SMADs are key intracellular mediators of transcriptional responses to TGF-β. SMAD4 is the pivotal factor of the TGF-β pathway and functions as a key tumor suppressor. Dysregulated SMAD4 expression has been reported in some cancers, including OS. 29 In this study, we aimed to identify the miRNA counterpart of TAZ and elucidate the mechanism underlying the effect of TAZ in OS. We found that TAZ expression is upregulated in OS tissues. Through miRNA sequencing, we investigated the potential roles of TAZ and its related target miRNA-224 (miR-224) in OS development. Then, we demonstrated that TAZ and miR-224 are tumor promoters that accelerate OS progression by promoting cell growth, invasion, tumorigenesis and metastasis. In addition, SMAD4 was identified as a protumorigenic gene and a direct functional target of miR-224 in OS. This study, for the first time, demonstrated the pro-OS effect of TAZ and miR-224, both in vitro and in vivo. Our results may provide the basis for a novel treatment and diagnosis strategy for TAZ-upregulated OS.
Results
TAZ expression was higher in OS patient tissues than in chondroma-innocent tumor tissues. Expression of TAZ was detected in OS and control tissues. In most human chondroma-innocent tumor tissues (90%, 18/20), only a low level of TAZ or vacant labeling was detected ( Figure 1A (ac) ). In contrast, strong staining for TAZ was observed in most of the OS tissues (81.25%, 13/16; Figure 1A (e-g)). Relative TAZ mRNA expression was significantly higher in OS tissues than in chondroma tissues or normal bone tissue (Po0.01; Figure 1B ). Consistent with these observations, OS cell lines U2OS, SAOS2, HOS, SjSA-1 and MG-63 were found to express higher levels of TAZ protein and mRNA relative to normal human osteoblastic cell line, as measured by western blotting and real-time PCR (Figures 1C and D) . miR-224 mediates the oncogenic potential of TAZ. To investigate whether miRNAs mediate TAZ functions, we profiled TAZ-induced miRNAs in MG-63 cells by highthroughput sequencing (Figure 3a) . Validation of the hits revealed that miR-224 was induced by TAZ. Interestingly, the profile of the upregulated miRNAs in OS compared with those in normal tissue showed that miR-224 also acted as a potential oncogene in OS (Supplementary Table 1 To test whether miR-224 could promote the growth of OS tumors in vivo, we engineered MG-63 cells to stably knockdown miR-224. These stably miR-224 sponge and control cells were subcutaneously inoculated into nude mice. As shown in Figure 4g , the tumors in the MG-63/miR-224 sponge group grew far less rapidly than the tumors in the MG-63/ vector group. miR-224 mediates the oncogenic potential of TAZ in OS cells in vitro. To elucidate whether the pro-tumorigenic function of TAZ was mediated by miR-224, we performed co-transfection studies. Interestingly, enhancement of miR-224 by the miRNA mimic hampered the growth inhibition induced by TAZ shRNA-treatment (Figure 5a ). Consistently, expression of miR-224 cooperated with TAZ shRNA, and led to a decrease in the cell apoptosis rate (Figure 5b ). Remarkably, overexpression of miR-224 clearly abrogated the TAZ shRNA-induced diminution of migration and invasion in both U2OS and MG-63 cells (Figures 5c and d) . Moreover, overexpression of miR-224 also strongly rescued TAZ knockdown-induced anchorage-independent growth inhibition ( Figure 5e ). Besides, we investigated whether further increase of miR-224 level would promote the TAZ-induced transformation of OS cells. Indeed, a combination of TAZ shRNA and premiR-224 was able to promote cell colony formation (Figure 5f ). These data provided further evidence that miR-224 is a TAZ target gene important for overproliferation and tumorigenesis in vitro.
miR-224 mediates the tumorigenic function of TAZ in vivo. To examine the in vivo pro-tumor growth effects of miR-224 in OS, MG-63 cell lines with TAZ knockdown, or transfected with pre-miR-224 and control vector, were subcutaneously injected into nude mice, and tumor growth was evaluated. MG-63 cells with TAZ knockdown and miR-224 upregulation exhibited a significantly higher growth rate than that of TAZ-knockdown cells (Figures 6a and b) . Inversely, knockdown of TAZ in MG-63 cells caused a substantial reduction in tumor volume in vivo (Figure 6c) , whereas co-expression of shTAZ and pre-miR-224 rescued the decrease in tumor volume. In addition, the differences in tumor average wet weight among the three groups were similar to the differences in tumor volume (Figure 6d ). The knockdown expression efficiency of TAZ is illustrated in Figure 6e . Thus, miR-224 is a TAZ target gene and is important for tumorigenesis in vivo.
SMAD4 is a target of miR-224 in OS. To dissect how miR-224 functions downstream of TAZ, we used the PicTar and TargetScan algorithms to predict potential miR-224 targets. Among these targets, the 3′-untranslated regions (UTRs) of SMAD4 mRNAs contained sequences complementary to the miR-224 seed sequence (Figure 7a ). We focused on SMAD4 because it has a tumor-suppressive role in carcinogenesis. To verify whether SMAD4 is a direct target of miR-224, we constructed a SMAD4 3′-UTR sensor and cotransfected the 3′-UTR and pre-miR-224 in 293T cells. Consistent reduction in luciferase activity for SMAD4 3′-UTR by miR-224 was observed (Figure 7b ). To validate target specificity, we generated mutated forms of the 3′-UTR, where the binding sites of miR-224 were destroyed using the QuikChange Mutagenesis Kit. Briefly, there are two miR-224-binding sites on the 3′-UTR of SMAD4. Co-transfection of pre-miR-224 with the mutated forms of the 3′-UTRs significantly attenuated the reduction of luciferase activities on wild-type (WT) 3′-UTR (Figure 7b ), indicating specific binding of miRNA and target SMAD4 3′-UTR. Furthermore, transfection of the miR-224 mimic or expression of premiR-224 substantially repressed endogenous SMAD4 protein level (Figure 7c, Supplementary Figure S2a) . Moreover, inhibition of endogenous miR-224 by an inhibitor antisense oligomer or miRNA sponge clearly increased SMAD4 protein levels in both cell lines (Figure 7c, Supplementary  Figure S2b) . However, miR-224 did not significantly alter the SMAD4 mRNA level (Figure 7d ), suggesting the presence of an underlying mechanism for translation repression.
Together, these results suggest that SMAD4 is a miR-224 target that is critical for growth regulation.
SMAD4 has essential roles in the manifestation of miR-224-induced phenotypes. Given the functional importance of SMAD4 on miR-224-mediated cell growth and migration in OS cells, we co-transfected SMAD4 and the miR-224 mimic into U2OS and MG-63 cells. miR-224-induced cell proliferation and migration was partially blocked by SMAD4 overexpression (Figures 8a and b, Supplementary  Figures S3a and b) in both U2OS and MG-63 OS cells. SMAD4 has an essential role in the TGF-β signaling pathway, where it binds to SMAD2/3 and translocates to the nucleus upon TGF-β stimulation. 30 To evaluate whether miR-224 affects TGF-β signaling by targeting SMAD4, we further treated miR-224-overexpressing and control cells with TGF-β. miR-224 impaired the TGF-β-induced nuclear transportation of SMAD4 to some extent (Figure 8c ), and accordingly, miR-224 markedly attenuated the TGF-β-induced restrain of cell growth and migration in MG-63 cells (Figures 8d and e) . These results suggest that miR-224 has a momentous role in the TGF-β signaling pathway by targeting SMAD4 in OS. Furthermore, we generated cells with stable knockdown of SMAD4, and further transfected them with miR-224 sponge. miR-224 knockdown had no impact on SMAD4 knockdowninduced cell proliferation (Figure 8f ), migration (Figure 8g ) or tumorigenesis (Figure 8h ). Together, these results suggest that SMAD4 has essential roles in the manifestation of miR-224-induced phenotypes.
SMAD4 has essential roles in the manifestation of TAZinduced phenotypes. Given the functional importance of miR-244 on TAZ-mediated cell growth and migration in OS cells, we next sought to elucidate the function of SMAD4 in TAZ-induced phenotypes. Similar to miR-224, expression of TAZ substantially repressed endogenous SMAD4 protein levels (Figure 9a ). Moreover, inhibition of endogenous TAZ by shRNA clearly increased SMAD4 protein levels in both cell lines (Figure 9a ). However, TAZ did not significantly alter SMAD4 mRNA levels (Figure 9b ). Through inhibition of TAZ, the Hippo pathway kinases may function as positive regulators of SMAD4 protein expression. Indeed, knockdown of Lats1/2 decreased SMAD4 protein levels ( Figure 9c) .
Next, we co-transfected SMAD4 and TAZ into U2OS and MG-63 cells. TAZ-induced cell proliferation and migration was partially blocked by SMAD4 overexpression (Figures 9d and  e) in both U2OS and MG-63 OS cells. Further, we generated cells with stable knockdown of SMAD4, and then Overexpression of TAZ and miR-224 significantly inhibited BMPinduced transcriptional activation of the natural Id1 promoter (Figures 10a and e) , as well as TGF-β-induced transcriptional activation (Figures 10b and f) in both the cell lines.
To further characterize the effect of TAZ and miR-224 overexpression on the expression of endogenous TGF-β target genes, we examined the levels of p15Ink4b and p21Cip1 mRNAs in cells overexpressing TAZ and miR-224. Although TGF-β upregulated the mRNA levels of both p15Ink4b and p21Cip1, overexpression of TAZ (Figures 10c (Figures 10g and h ) decreased these levels in U2OS and MG-63 cells. Similarly, PAI-1 mRNA levels were upregulated and diminished in response to TGF-β treatment and overexpression of TAZ (Figures 10c and d) and miR-224 (Figures 10g and h ), respectively. We next investigated whether overexpression of TAZ and miR-224 potentiates BMP responses. Notably, overexpression of TAZ (Figures 10c and d) and miR-224 (Figures 10g and h ) markedly decreased the expression of BMP downstream genes such as Id1 and SMAD6 in U2OS and MG-63 cells. Together, these data strongly suggested that TAZ and miR-224 are both regulators of TGF-B and BMP signaling.
Discussion
The Hippo pathway has a dominant role in organ size control, growth and development, and tissue homeostasis. Recently, increasing evidences have revealed the close relationship of the Hippo pathway with malignant tumors. As a regulator and vital molecule in the upstream reactions of the tumorsuppressor pathway, mutation or deletion of the Hippo pathway upregulates YAP/TAZ expression, which promotes tumorigenesis and influences prognosis. 31, 32 YAP regulates the corresponding procedures by controlling miRNAs. However, few studies have demonstrated the regulation of miRNAs through TAZ. The Hippo pathway is highly complex and variable, with multiple cross-talks with other signaling pathways. 33 Notably, miR-29 has been identified as a YAP target gene mediating cross talk with the mTOR pathway and affecting cell size. 34 These results suggested that the mammalian Hippo pathway could function via miRNA targets. Moreover, recently, a functional miR-130a mediating the organ size control activity of YAP in vivo was identified. 6 TAZ is a homolog of YAP that contributes to preserving the pluripotency of breast cancer, 35, 36 and the results of this study suggest that it is overexpressed in OS tissues and cells. However, few researchers have reported that miRNA mediates TAZ function and that TAZ regulates miRNA. In this study, cell lines with upregulated TAZ expression were chosen to study the regulation of miRNA by TAZ. We found TAZ-regulated miR-224 and TAZ were both associated with the TGF-β pathway. Our results showed that the regulatory network of miR-224 has a significant effect on proliferation, invasion and migration.
The TGF-β and Hippo pathways exhibit cross-talk in the tumorigenesis of OS. 37 The downstream molecules of the TGF-β and Hippo pathways function as transcriptional regulators, controlling the transcription of target genes. In a previous study, YAP/TAZ restricted the accumulation and transcriptional activity of SMAD when an aberrant Hippo pathway was activated. 38 In dense cells, the Hippo pathway was activated, and YAP/TAZ was restrained within the cells. Then, SMAD attenuated TGF-β transcription, which in turn suppressed epithelial-to-mesenchymal transition (EMT). 39 The Hippo pathway influences SMAD function through miRNA, and has a vital effect on stem cells, cancer stem cells, and strong proliferative cells. Previously, we believed that YAP/TAZ possessed dual function, including the promotion of proliferation by upregulating CTGF and BIRC5 and inhibition of apoptosis by downregulating the corresponding genes. For instance, overexpression of YAP/TAZ or aberrant activation of YAP/TAZ caused by mutations of other factors in the Hippo pathway could facilitate the expression of downstream transcription factors like cyclin E and DIAP1, which led to the inhibition of apoptosis. 40 Our model described and complemented the anti-apoptotic function of TAZ and enriched the variability of the network involving TGF-β, miRNA and Hippo.
The TGF-β signaling pathway induces EMT during cancer progression. A recent report revealed that CTGF is required for TGF-β-induced EMT. 41 Although TAZ is thought to contribute to EMT, 42 the molecular mechanism by which the transcription factor achieves its deleterious effects is unknown. Although we identified the cross talk of the two pathways and demonstrated that miR-224-mediated migration is controlled by TAZ, the specific mechanisms of invasion and migration need to be clarified in future studies.
In conclusion, in this study, we demonstrated that the expression levels of TAZ and miR-224 are upregulated in OS tissues. Moreover, we proposed a novel TAZ-miR-224-SMAD4 axis in OS cells that mediates cell invasion and migration, and drives cell proliferation and tumor growth. These findings suggest that TAZ and miR-224 may represent new targets for OS therapy. Notably, the similarity of YAP and TAZ in TEADbinding indicates that YAP may mediate miR-224 onco-activity in a similar manner, although we did not investigate the role of miR-224 in mediating YAP function in this study. Technical advances on antisense miRNA oligomers (antimiRs) have rendered miRNAs drug targets for anticancer therapy with unique advantages. 43 Thus, the identification of the remarkable role of miR-224 in sustaining TAZ activity would pave the way for modulating TAZ-miR-224 and TGF-β as exciting new therapeutic targets for OS with high TAZ expression.
Materials and Methods
Ethics. All animal experiments were carried out according to relevant national and international guidelines and approved by the Stanford Institutional Animal Care and Use Committee (IACUC). All experiments strictly followed the panel's specific guidelines regarding the care, treatment and killing of animals used in the study. Immunohistochemistry staining. Immunohistochemical analysis was performed. The primary antibodies against TAZ was diluted 1 : 200 and were incubated at 4°C overnight in a humidified container. After washing with PBS three times, the tissue slides were treated with a non-biotin horseradish peroxidase detection system according to the manufacturer's instructions (Dako, Copenhagen, Denmark).
Antibodies, plasmids, mice and other materials. Information regarding the materials used in this study is included in the Supplementary Materials and Methods.
Cell culture, transfection and viral infection. Cell culture procedures are described in the Supplementary Materials and Methods.
Xenograft tumorigenesis model. Nude mice (nu/nu, male 3-to 4-weekold) were injected subcutaneously with 1 × 10 7 MG-63 stable cells. Tumor volumes were calculated from the length (a) and the width (b) by using the following formula: volume (ml 3 ) = ab 2 /2. Five weeks after injection, the animals were killed, and tumors were harvested (measured and weighed) and fixed in 4% paraformaldehyde. Wet tumor weight was calculated as mean weight ± S.D. in each group.
Luciferase assays. For miR-224 promoter reporter and 3′-UTR reporter luciferase assays, HEK293T cells were transfected with the reporter, together with CMV-β-gal and the indicated plasmids. Twenty-four hours after transfection, cells were lysed. Luciferase activity was measured by using the Luciferase Assay System (Promega, Madison, WI, USA) following the manufacturer's instructions. All luciferase activities were normalized to β-gal activity.
For TGF-β and BMP luciferase reporter assays, Id1-luc and SBE-OC-luc were used to measure BMP-induced transcription, and SBE-luc for TGF-β-induced transcription. Cells were transfected with reporter plasmids together with Renilla luciferase plasmid to normalize transfection efficiency. Briefly, 24 h after transfection, cells were treated with BMP2 (20 ng/ml) or TGF-β (2 ng/ml) for 12 h. Cells were then harvested, and luciferase activity was measured using Dual-Luciferase Reporter Assay System (Promega). All assays were carried out in triplicate and normalized against Renilla Luciferase activity.
Chromatin immunoprecipitation (ChIP). ChIP assay was performed using the Millipore ChIP kit (Millipore, Billerica, MA, USA) according to the manufacturer's instructions. Briefly, cells were cross-linked and lysed, and DNA fragments were sonicated to an average size of 0.5 kb. ChIP was then performed using 5 μg antibodies against Flag or control IgG, after 14 h of incubation. The immunoprecipitants were washed and eluted. The eluents were then de-crosslinked, and DNA was purified for polymerase chain reaction (PCR) analysis.
RNA isolation and real-time PCR. To determine the mRNA expression levels of regular genes and pri-miR-224, total RNA was isolated from cultured cells using TRIzol reagent (Life Technologies, Carlsbad, CA, USA). cDNA was synthesized by reverse transcription using random hexamers and subjected to real-time PCR with the indicated primers in the presence of SYBR Green (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA, USA). β-Actin was used as a standard for normalization. miRNAs were extracted using the mirVanamiRNA isolation kit (Life Technologies). The relative expression levels of the miRNAs were determined using TaqmanmiRNA Assays (Life Technologies) normalized to RNU6B. All experiments were performed at least in triplicate. Detailed experimental procedures can be found in the Supplementary Materials and Methods.
Migration and invasion assays. Invasion assays were performed using a 24-well invasion chamber system (Corning Inc., New York, NY, USA). Cells were trypsinized and counted with a hemocytometer using Trypan blue, and viable cells were seeded in the upper chamber at a density of 3 × 10 4 cells per well in serum-free medium. The lower chamber received 500 μl of 10% fetal bovine serum-containing medium. Incubation was carried out for 36 h at 37°C in humidified air with 5% CO 2 . Migrated cells on the lower surface were fixed with methanol and stained with Giemsa. The number of migrating cells was determined by counting five high-powered fields (200 × ) on each membrane. The migration assay was a modification of the invasion assay described previously. A total of 3 × 10 4 cells were placed in the upper chamber in serum-free medium. The lower chamber was filled with medium containing 10% fetal bovine serum. Cells were allowed to migrate through a porous, uncoated membrane for 24 h at 37°C. The membrane was processed as described for the invasion assay. The number of migrating cells was determined by counting five highpowered fields (200 × ) on each membrane. Each test group was assayed in triplicate.
MTT assay, colony formation assay, soft agar colony formation assay, apoptosis flow cytometry and immunohistochemistry. The MTT assay, colony formation assay, soft agar colony formation assay, apoptosis flow cytometry and immunohistochemistry (IHC) were conducted according to previously described methods. 44 Further details are provided in the Supplementary Materials and Methods.
Statistical analysis. Statistical analyses were performed with SPSS (SPSS Inc, Chicago, IL, USA). Data are represented as means with S.D., and statistical significance was determined with unpaired Student's t-tests, unless indicated otherwise. P-values o0.05 were considered statistically significant.
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